The Medical Letter®
On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

IN THIS ISSUE (starts on next page)

In Brief: Fexofenadine (Allegra) and Fruit Juice .. p 41

Important Copyright Message

The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints
or call customer service at: 800-211-2769

FORWARDING OR COPYING IS A VIOLATION OF US AND INTERNATIONAL COPYRIGHT LAWS
**Fexofenadine (Allegra) and Fruit Juice**

Fexofenadine (Allegra, and others) is the most recent second-generation H₁-antihistamine to become available over the counter (OTC). Cetirizine (Zyrtec, and others) and loratadine (Claritin, and others) are already available OTC. Cetirizine can be sedating in usual doses. Loratadine can be sedating in higher-than-usual doses. Fexofenadine remains nonsedating even in higher doses.¹

The manufacturer of Zyrtec has responded to this new OTC product with television advertisements drawing attention to the label warning against taking fexofenadine with fruit juice. Many fruit juices such as grapefruit, orange and apple juice are organic anion transporting peptide (OATP) 1A2 inhibitors. OATP1A2 transporters are involved in the absorption of fexofenadine from the gastrointestinal tract. Inhibition of the activity of intestinal OATP1A2 reduces serum concentrations of fexofenadine by up to 70%, possibly reducing its effectiveness.² Patients can avoid this interaction by not drinking fruit juice within 4 hours before or 1-2 hours after taking fexofenadine.

---